Psoroptes ovis mange in sheep: Organ and tissue weights as indicators of the impact on organismal metabolism, lymphatic system and body composition.

Although adverse effects on the welfare, skin pathology and host immune responses of ovine psoroptic mange are well described, there is only limited research on the impact on the performance of the animals and underlying pathogenicity. To provide objective data on effects of the disease at organismal level, weights of organs and tissues of sheep included in a parasiticide study with groups of mange-infested, mange-infested and treated and non-infested animals were evaluated. For the study, 48 young Merino sheep were formed randomly into three equal-sized groups on sex and body weight - to develop mange without intervention ('infested'), to develop mange and treated 10 weeks after initial infestation ('infested-treated') or to be prevented from mange infestation - and infested twice with Psoroptes ovis mites.

Sarcoptic mange in cattle: Effects of treatment with eprinomectin topical solution on performance, behavior changes, and adrenal and systemic responses to ACTH challenge.

Bovine sarcoptic mange can cause significant pruritus and skin disease which compromise the health and welfare of the animals, impairs animal productivity and is furthermore of zoonotic concern. This study was conducted to evaluate the effects of efficacious treatment of sarcoptic mange on performance and on animal welfare using behavioral indicators and adrenal reactivity testing. Sixteen young cattle with induced sarcoptic mange were allocated by restricted randomization based on body weight to an untreated group (control) or a treated group (eprinomectin 5 mg/mL topical solution [EPRINEX® Pour-On] at Day 0) and monitored for eight weeks after treatment administration (mite counts, lesion scores, anti-Sarcoptes antibodies, feed intake, body weight, 24-hour behavior videotaping, adrenocorticotropic hormone [ACTH] stimulation at Day 58).

Efficacy of eprinomectin 5 mg/mL topical solution administered pour on at 1 mg per kg body weight against Oestrus ovis myiasis in sheep and goats.

The larvae of the nasal bot, Oestrus ovis, mainly parasitize sheep and goats and some species of wild Caprinae but other mammals and humans are also vulnerable to infestation. Eprinomectin 5 mg/mL topical solution (EPRINEX® Multi, Boehringer Ingelheim) administered at 1 mg eprinomectin per kg body weight pour on was recently authorized as an anthelmintic for sheep and goats with zero hours milk withdrawal in several countries in Europe. As the product in cattle has claims against a broad range of parasites including insect parasites and activity against O.

Gamithromycin in swine: Pharmacokinetics and clinical evaluation against swine respiratory disease.

The pharmacokinetics of gamithromycin were evaluated in 26 male castrated and female crossbred swine administered gamithromycin 15% w/v (Zactran®, Boehringer Ingelheim) intravenously at 6 mg/kg bodyweight or intramuscularly at 3, 6 or 12 mg/kg bodyweight. Blood samples were collected up to Day 10 to establish the plasma profile of gamithromycin, bioavailability and dose proportionality. When administered by intramuscular injection at 6 mg/kg BWT, pharmacokinetic parameters were as follows: area under the curve until last quantifiable plasma concentration, 5.

Eprinomectin pour-on: Prevention of gastrointestinal and pulmonary nematode infections in sheep.

The present study was conducted to further characterize the anthelmintic activity of the 0.5% w/v topical formulation of eprinomectin (EPRINEX Pour-on, Merial) when administered at 1 mg/kg body weight to sheep in preventing the establishment of induced gastrointestinal and pulmonary nematode infections. Thirty-six female Merino sheep (∼4 months of age, weighing 27.

Eprinomectin pour-on (EPRINEX® Pour-on, Merial): efficacy against gastrointestinal and pulmonary nematodes and pharmacokinetics in sheep.

Background: The anthelmintic efficacy of the 0.5% w/v topical formulation of eprinomectin (EPN), EPRINEX® Pour-on (Merial) when administered at 1 mg/kg body weight was evaluated in sheep in two dose confirmation laboratory studies and one multicenter field study. In addition, the pharmacokinetics of EPN when administered at that dosage to adult sheep was determined.